Product Images Capecitabine

This is a medication called Capecitabine with each tablet containing 150mg of the drug. It is a cytotoxic agent and should be kept out of children's reach. The recommended storage temperatures are between 20°C - 25°C. The pharmacist must dispense the medication in its original container and provide patient information. The drug is manufactured by Hikma Pharmaceuticals USA Inc. and marketed by GSMS, Incorporated. The prescribing information should be consulted for dosage instructions. Contains FD&C Yellow No.6 coloring.*

This is a prescription drug called capecitabine. Each tablet has 500mg of capecitabine, and there are 20 tablets in the package. It is a cytotoxic agent, and its dosage information can be found in the included prescribing information. It contains FD&C Yellow No.6 as a color additive. Patients should receive patient information along with the prescription, and the medication should be stored at controlled room temperature. It is manufactured by Hikma Pharmaceuticals USA Inc. and marketed by GSMS, Incorporated in Camarillo, CA.*

available*

This is a chart displaying estimated probabilities related to a specific treatment plan involving Docetaxel and Capecitabine for a certain duration of time (measured in days). The chart shows probabilities for a specific group of patients and the dosage is measured in milligrams per meter square given over a period of weeks. It seems to be a study or analysis of the treatment effectiveness.*

This text appears to be a graph with some labels indicating time (in days) and dosages for two different drug regimens for cancer treatment. The graph seems to compare the efficacy of "5-FU + Leucovorin (Mayo Regimen)" against "Capecitabine" over a period of 1500 days. Without the visual representation, it is difficult to infer any additional information.*

This appears to be a graph showing estimated probabilities of an event over time, with two treatment groups labeled as "Docetaxel" and "Capecitabine". The x-axis represents time (measured in days) and the y-axis represents the estimated probability of the event. The specific event being studied is not clear from the given text.*

This appears to be a table or chart related to survival rates of patients on different cancer treatments over a period of time. The treatments being compared are 5FU+Leucovorin and CAPECITABINE. The chart suggests that survival rates for patients taking 5FU+Leucovorin were higher than those taking CAPECITABINE.*